Susan Berson and Brent Henry Recognized as Health Care Trailblazers by the National Law Journal

Mintz advised the underwriters in connection with Cogent Biosciences, Inc.’s concurrent public offerings of $345 million of common stock (the “Equity Offering”) and $230 million in aggregated principal amount of 1.625% convertible senior notes due 2031 (the “Convertible Notes Offering”).

Mintz advised the underwriters in connection with Verastem Oncology’s $103 million public offering.

Mintz advised the underwriter in connection with a $75 million registered direct offering by Precision BioSciences, Inc. 

Mintz advised Diamond Antenna and Microwave Corporation, a developer of advanced radio frequency and electro-mechanical solutions and a portfolio company of Artemis Capital Partners, on its acquisition of Antenna Associates, a developer of antenna systems for military and commercial applications. This transaction follows Mintz’s representation of Artemis in its 2024 acquisition of Diamond Antenna and Microwave Corporation.

Mintz advised the underwriters in connection with a $50 million follow-on offering by Eledon Pharmaceuticals.

Mintz advised the underwriters in connection with Benitec Biopharma’s follow-on public offering of 5,930,000 shares of common stock at a public offering price of $13.50 per share, and the placement agents in the concurrent registered direct offering of 1,481,481 shares of common stock at an offering price of $13.50 per share. The aggregate gross proceeds to Benitec Biopharma from these offerings were approximately $100 million before deducting underwriting discounts and commissions, placement agent fees, and other offering expenses. In addition, Benitec Biopharma granted the underwriters a 30-day option to purchase up to an additional 889,500 shares of its common stock at the public offering price.